|
1
|
Özdemir Ö, Dikici Ü. COVID-19 and vaccination in hereditary angioedema: Single center experience. World Allergy Organ J 2024; 17:100892. [PMID: 38559494 PMCID: PMC10973662 DOI: 10.1016/j.waojou.2024.100892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 02/26/2024] [Accepted: 03/05/2024] [Indexed: 04/04/2024] Open
Abstract
Like many microbial agents, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its vaccination may increase the frequency and/or severity of attacks. We aimed to observe/evaluate patients with hereditary angioedema (HAE) followed by Sakarya University Research/Training Hospital pediatric allergy unit, Sakarya, Türkiye, for the effects of SARS-CoV-2 infection and COVID-19 vaccination. Ten HAE patients-3 males and 7 females-were evaluated retrospectively. Their mean age was 31.80 ± 19.15 (min. 12 - max. 66) years. Four of 10 patients were diagnosed with type 1 HAE and 6 with type 2 HAE. Two out of 6 patients (mother and daughter) diagnosed with type 2 HAE had angioedema attacks during COVID-19 disease. Six out of 10 HAE patients received different COVID-19 vaccines available in Türkiye up to third and fourth doses. There was no increase in COVID-19 vaccine-related attacks during, after 72 hours, and up to the year after vaccination. As a result, we consider it safe to administer inactivated and/or mRNA vaccines in our patients with HAE. In addition, catching SARS-CoV-2 infection was not always associated with disease exacerbation or activation.
Collapse
Affiliation(s)
- Öner Özdemir
- Division of Allergy and Immunology, Department of Pediatrics, Sakarya University Faculty of Medicine, Research and Training Hospital of Sakarya University, Sakarya, Türkiye
| | - Ümmügülsüm Dikici
- Division of Allergy and Immunology, Department of Pediatrics, Sakarya University Faculty of Medicine, Research and Training Hospital of Sakarya University, Sakarya, Türkiye
| |
Collapse
|
|
2
|
Nicola S, Mazzola M, Lo Sardo L, Montabone E, Badiu I, Corradi F, Azzolina MCR, Dall’Acqua MG, Rolla G, Ridolfi I, Quinternetto A, Brussino L. Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy. Vaccines (Basel) 2024; 12:202. [PMID: 38400185 PMCID: PMC10893122 DOI: 10.3390/vaccines12020202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/02/2024] [Accepted: 02/08/2024] [Indexed: 02/25/2024] Open
Abstract
Background In the past three years, COVID-19 has had a significant impact on the healthcare systems and people's safety worldwide. Mass vaccinations dramatically improved the health and economic damage caused by SARS-CoV-2. However, the safety of COVID-19 vaccines in patients at high risk of allergic reactions still has many unmet needs that should be clarified. Material and methods A retrospective, single-centre study was performed by collecting demographic and clinical data of patients with Mast Cell Disorders (MCDs) to evaluate the safety and tolerability of COVID-19 vaccinations. Moreover, any changes in the natural history of the underlying disease following the vaccine have been evaluated. Results This study included 66 patients affected with MCDs. Out of them, 52 (78.8%) received a COVID-19 vaccination and 41 (78.8%) completed the vaccination course. Premedication came first in 86.6% of our patients. A total of seven (4.5%) patients complained about an immediate reaction and two (1.3%) had a late reaction. Worsening of MCD history was observed in a single patient. Conclusions Despite the overall high risk of allergic reactions, our study did not reveal any increased risk for SARS-CoV-2 allergic reactions in MCD patients, thus supporting the recommendation in favour of the SARS-CoV-2 vaccination. However, due to the potentially increased rate of anaphylactic reactions, MCD patients should receive vaccine premedication and should be treated in a hospital setting after an allergological specialistic evaluation.
Collapse
Affiliation(s)
- Stefania Nicola
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Marina Mazzola
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Luca Lo Sardo
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
| | - Erika Montabone
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Iuliana Badiu
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
| | - Federica Corradi
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
| | - Maria Carmen Rita Azzolina
- Health Direction, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (M.C.R.A.)
| | | | - Giovanni Rolla
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Irene Ridolfi
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Anna Quinternetto
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| | - Luisa Brussino
- SCDU Immunologia e Allergologia, A.O. Ordine Mauriziano di Torino, C.so Re Umberto 109, 10128 Torino, Italy; (S.N.); (M.M.); (L.L.S.); (E.M.); (I.B.); (F.C.); (A.Q.); (L.B.)
- Department of Medical Sciences, University of Torino, C.so AM Dogliotti, 14, 10126 Torino, Italy;
| |
Collapse
|